Melanoma: dieci anni di rivoluzione, dieci anni di Bridge
Paolo Ascierto
Direttore SC Oncologia Medica Melanoma Immunoterapia Oncologica e Terapie Innovative
Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli
BRIDGE
-
A model system to understand immunotherapy resistance
Georgina Long
Co-Medical Director
Melanoma Institute Australia, Sidney -
Immunotherapy response rates in lymphomas
John Timmerman
Division of Hematology-Oncology – David Geffen School of Medicine
UCLA Medical Center, Los Angeles
Trial design: no pain, no gain
Omid Hamid
Director Immunotherapy and Translational Research
The Angeles Clinic and Research Institute, Los Angeles -
Nutrition and immunotherapy response
Jennifer McQuade
Department of Melanoma Medical Oncology
University of Texas MD Anderson Cancer Center, Houston
The PIVOT-02 trial
Igor Puzanov
Director Early Phase Clinical Trials and Melanoma Program
Roswell Park Cancer Center, Buffalo